ORKA
NASDAQ HealthcareOruka Therapeutics, Inc. - Common Stock
Biotechnology
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
๐ Market Data
| Price | $112.66 |
|---|---|
| Volume | 495,335 |
| Market Cap | 7.46B |
| RSI (14-Day) | 80.9 Overbought |
| 200-Day MA | $53.20 |
| 50-Day MA | $87.82 |
| 52-Week High | $113.04 |
| 52-Week Low | $14.08 |
| Forward P/E | -40.64 |
| Price / Book | 6.19 |
๐ฏ Investment Strategy Scores
ORKA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (95/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ORKA in your text
Paste any article, transcript, or post โ the tool will extract ORKA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.